PECAM-1/CD31 is vascular cell adhesion and signaling molecule of the Ig superfamily that plays a role in neutrophil recruitment at inflammatory sites and may be involved the release of leukocytes from the bone marrow and in cardiovascular development. The interactions of PECAM-1 with its ligands are complex in that it is able to bind both with itself (homophilic adhesion) or with non-PECAM-1 ligands (heterophilic adhesion). Although the factors that regulate ligand binding are not fully understood, these interactions are regulated in part by its large cytoplasmic domain, a region of 118 amino acids encoded by 8 exons of its gene (exons 9 -16). The purpose of this work was to better define the mechanisms of PECAM-1-dependent homophilic adhesion by analyzing the binding interactions of L-cells expressing full-length and selectively mutated forms of human, murine, and human/murine chimeric PECAM-1 molecules in an established aggregation assay. These studies demonstrate that 1) the minimal length of the cytoplasmic domain required for cellular aggregation is represented within the sequences encoded by exons 9 and 10, 2) removal or addition of the sequences encoded by exon 14 from the cytoplasmic domain can determine whether the mechanism of aggregation is a heterophilic calciumdependent process or a homophilic calcium-independent process, 3) high levels of surface expression of PE-CAM-1 on the cell surface change the mechanism of aggregation from heterophilic to homophilic, and 4) PE-CAM-1-dependent homophilic binding appears to involve the direct interaction of only the first two extracellular Ig-like domains. These data suggest that PECAM-1-ligand interactions can be regulated through multiple pathways including alterations of the cytoplasmic domain and the level of surface expression.
Platelet endothelial cell adhesion molecule (PECAM-1/ CD31) 1 is a member of the immunoglobulin gene superfamily found on platelets, most leukocytes, and endothelial cells, where it concentrates at cell-cell borders (1) . Its ability to mediate cell-cell adhesion (2) and up-regulate integrin function (3) (4) (5) (6) , along with its unique cellular distribution, allows PE-CAM-1 to potentially play significant roles in a variety of important processes including leukocyte recruitment at inflammatory sites (7) (8) (9) (10) , regulation of release of bone marrow leukocytes (4) , and cardiovascular development (11) .
The interactions of PECAM-1 with its ligands are complex and still not fully understood. Like several other members of the immunoglobulin (Ig) superfamily (e.g. NCAM (12) , Ng-CAM (13), Nr-CAM (14) and biliary glycoprotein (15) ), PE-CAM-1 appears to be able to interact both with itself (homophilic adhesion) (2, 16 -18) or with non-PECAM-1 ligands (heterophilic adhesion). A proteoglycan containing heparin or chondrotin sulfate (18 -20) and the integrin ␣v␤3 (20, 21) have been identified as two possible heterophilic ligands for PECAM-1.
PECAM-1 possesses six Ig-like homology units (each encoded by a single exon) in its extracellular domain and a relatively large cytoplasmic domain (containing 118 amino acids) encoded by eight distinct exons (exons 9 -16) (22) . Specific regions have been identified in both the extracellular and cytoplasmic domains of the PECAM-1 molecule that appear to regulate the ability of the molecule to function in either heterophilic or homophilic binding. With regard to heterophilic adhesion, binding sites responsible for interactions with the two non-PECAM-1 ligands have been localized to regions in the second Ig-like domain of PECAM-1 (19 -21) . A region in the sixth Ig-like domain also appears to be involved, since two monoclonal antibodies mapping to this region can inhibit heparindependent heterophilic binding (23, 24) .
An understanding of the regions responsible for homophilic binding is less clear. From studies of PECAM-1 mutants fused to the Fc region of human IgG, it has been proposed that PECAM-1-dependent homophilic adhesion involves an interaction in which PECAM-1 on adjacent cells overlap each other in an antiparallel manner with engagement of specific binding sites in domains 2 and 3 and domains 5 and 6 (16) . However, these observations were not conducted in a cell-cell system, but were made using artificial PECAM-1 constructs in which the extracellular domains of the molecule were fused to an IgG framework requiring the removal of the cytoplasmic and trans-membrane domains. These alterations may be highly significant, since aggregation studies of L-cells expressing either human PECAM-1 (huPECAM-1) cytoplasmic domain deletion mutants or alternatively spliced cytoplasmic domain variants of murine PECAM-1 (muPECAM-1) suggest that the cytoplasmic domain plays an important role in regulating the ligand interactions of PECAM-1 (11, 23, 25) . Sun et al. (26) have also examined huPECAM-1 binding with a recombinant PECAM-1/ IgG chimeric protein but found that only domains 1 and 2 were required for homophilic binding. One goal of this study was to determine what regions in the extracellular domain were responsible for homophilic binding in a cell-cell system that includes the transmembrane and cytoplasmic domains of PECAM-1.
A number of other interesting and important questions remain about the mechanisms that regulate PECAM-1 homophilic binding. Since earlier studies have indicated the loss of the entire cytoplasmic domain of huPECAM-1 eliminates the ability of the molecule to support aggregation while smaller truncations convert heterophilic binding to homophilic binding (23) , another goal of this study was to evaluate the minimal region of the cytoplasmic domain that would support aggregation. Aggregation studies of L-cells transfected with alternatively spliced cytoplasmic domain variants of muPECAM-1 (11, 25) suggest that exon 14 may be a key region of the molecule with respect to regulating binding specificity. A third goal of this study was to specifically answer the question of whether exon 14 was necessary or sufficient to regulate heterophilic binding of huPECAM-1.
To answer these questions and to better define the mechanisms of PECAM-1-dependent homophilic adhesion, L-cells expressing full-length and selectively mutated forms of huPE-CAM-1 were analyzed in an established aggregation assay. These experiments demonstrated that the minimal region of the cytoplasmic domain that supported homophilic aggregation was contained exons 9 and 10. Similar to the observations with muPECAM-1, deletion of exon 14 converted the mechanism of adhesion of huPECAM-1 from a heterophilic calcium-dependent interaction to a homophilic calcium-independent process. The addition of exon 14 to a mutant expressing a cytoplasmic domain consisting of only exons 9 and 10 converted homophilic binding to heterophilic, although this effect seemed to be dependent on the level of PECAM-1 surface expression. This observation led to the surprising finding that cells expressing very high levels of the full-length form of huPECAM-1 aggregated in a homophilic rather than heterophilic manner. Additional studies were carried out taking advantage of the fact that L-cells expressing muPECAM-1 did not interact with Lcell transfectants of huPECAM-1. Using L-cell transfectants with targeted mutations in the extracellular domain, it was determined that huPECAM-1-dependent homophilic interactions could occur if only the first two domains of the molecule were human but did not occur if either of the first two Ig-like domains were changed to the corresponding sequence of mu-PECAM-1. These data suggest that huPECAM-1-dependent homophilic adhesion is primarily dependent on only the first two Ig-like domains, is regulated by the structure of the cytoplasmic domain (especially by the presence of exon 14) , and can be induced by increasing the level of surface expression. Fig. 1 )-A total of seven cytoplasmic domain mutants are described in this paper (summarized in Fig. 1 ). Six of these constructs are identified based on the exons that were deleted. For example, huPECAM-1⌬15,16 designates a human construct in which exons 15 and 16 were removed. huPECAM-1(ϩ)9,10,14 represents the human cytoplasmic domain mutant containing exons 9, 10, and 14.
EXPERIMENTAL PROCEDURES

Construction of Cytoplasmic Domain Mutants of huPECAM-1 (see
huPECAM-1⌬14 -16 and huPECAM-1⌬12-16 -The preparation of these constructs has been previously described (23) .
huPECAM-1⌬15,16 -To generate mutant cDNA, site-directed mutagenesis was performed on huPECAM-1 in the expression vector pESP-SVTEXP (pTEX) (23) using a "unique site elimination" site-directed mutagenesis protocol according to the manufacturer's instructions (Pharmacia Biotech Inc.) with a mutagenic primer carrying an in frame stop codon immediately following exon 14. The mutant huPE-CAM-1 was released from the plasmid by digestion with HindIII and AsuII, blunt-ended, and subsequently ligated into the pcDNAI/Neo expression vector digested previously with HindIII and EcoRV.
huPECAM-1⌬14 -To generate a construct missing exon 14, two PCR-generated sequences, a 5Ј fragment (from the NheI restriction site to the end of exon 13) and a 3Ј fragment (from the beginning of exon 15 to the AsuII restriction site) were joined together by sequence overlap extension (SOE) technique (27) . The gel-purified 5Ј and 3Ј fragments were then used as templates and "SOEed" together to create a 673-base pair fragment using the sense primer for the 5Ј fragment and antisense primer for the 3Ј fragment. The gel-purified PCR-SOE fragment was digested with NheI and AsuII and ligated into pTEX/ huPECAM-1 digested with the same enzymes. (pcDNAI/Neo/huPECAM-1) digested with the same enzymes.
huPECAM-1⌬11-16 and huPECAM-1⌬10 -16 -PCR-generated sequences with NheI and AsuII restriction sites at the 5Ј and 3Ј ends, respectively, were produced using a sense primer complimentary to unique NheI restriction site and antisense primers complimentary to the end of exons 10 (for huPECAM-1⌬11-16) and 9 (for huPECAM-1⌬10 -16), each with an in frame stop codon and an AsuII restriction site at the 5Ј end. The gel-purified PCR products were digested with NheI and AsuII and ligated into pTEX/huPECAM-1 previously digested with NheI and AsuII. The mutant cytoplasmic domains were released form the pTEX vector by BstEII and AsuII (for huPECAM-1⌬11-16) and BstEII and NotI (for huPECAM-1⌬10 -16) and were subsequently ligated into appropriately digested pcDNAI/Neo/huPECAM-1.
huPECAM-1(ϩ)9,10,14 -Taking advantage of the fact that there is a BglII restriction site on the border of exon 13 and exon 14, a PCRgenerated sequence containing exons 9 and 10 with NheI and BglII restriction sites at the 5Ј and 3Ј ends, respectively, were produced using a sense primer complimentary to the NheI restriction site and an antisense primer complimentary to the end of exons 10 with a BglII restriction site. The gel-purified PCR product was digested with NheI and BglII and ligated into the pTEX vector containing huPE-CAM⌬15,16 digested with the same enzymes. Mutant huPECAM-1 cytoplasmic domain was released by digestion with BstEII and AsuII and ligated into pcDNAI/Neo/huPECAM-1 digested with BstEII and EcoRV.
Construction of Human/Mouse PECAM-1 Chimeric Mutants (see Fig.  2 )-A total of four human/mouse chimeric mutants are described in this paper (summarized in Fig. 2) . The constructs are named by assuming a human PECAM-1 backbone followed by a listing of any regions of the molecule that contain mouse sequences. Thus, huPECAM-1D3-6 mu represents human PECAM-1 with Ig-domains 3-6 removed and replaced with the homologous mouse Ig domains 3-6.
Full-length huPECAM-1 and muPECAM-1-The cloning of huPE-CAM-1 in the expression vector pESP-SVTEXP (2) and muPECAM-1 in the pcDNAI/Neo vector (25) have been described previously.
huPECAM-1D3-6 mu -The preparation of the huPECAM-1 mutant in which domains 3-5 and most of domain 6 were replaced by the corresponding murine sequence has been previously described (24) .
huPECAM-1D1 mu , huPECAM-1D2 mu , and huPECAM-1D1,2 mu -To generate mutant cDNAs of human PECAM-1 in which domain 1 (hu-PECAM-1D1 mu ), domain 2 (huPECAM-1D2 mu ), or both (huPECAM-1D1,2 mu ) had been replaced by the corresponding murine sequence, the cDNA of huPECAM-1 with domain 2 deleted (huPECAM-1⌬2) in pTEX (19) was cut with two unique restriction endonucleases, ApaI and BstEII. ApaI cuts early in the signal sequence at base pair 159, while BstEII cuts at base pair 819, a site between the second and third Ig-like domains. Replacement sequences were then engineered for each construct in a two-step process in which two PCR-generated sequences (5Ј fragment and 3Ј fragment) were joined together by means of sequence overlap extension. The gel-purified 5Ј and 3Ј fragments were then used as templates and "SOEed" together to create inserts using the forward primer for the 5Ј fragment and the reverse primer for the 3Ј fragment. The replacement sequences were then digested with ApaI and BstEII and ligated into the previously digested huPECAM-1⌬2 plasmid construct. For huPECAM-1D1,2 mu and huPECAM-1D2 mu the resulting human/mouse sequence was released from the pTEX plasmid construct by digestion with XhoI and ligated into a similarly digested huPE-CAM-1 cDNA in the pcDNAI/Neo vector. For huPECAM-1D1, the plasmid was digested with StuI and SmaI, and the fragment containing the mutant was then blunt-end ligated into the huPECAM-1/pcDNAI/Neo vector digested with EcoRV.
Tissue Culture and Transfection of L-cells-Before transfection, all of the mutant constructs were sequenced in the regions of changes, and protein expression was confirmed in COS cells. L-cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and were cultured in RPMI medium with 10% fetal bovine serum. The procedures to transfect PECAM-1 cDNA into these cells have been previously described (2, 19) . Protein expression was confirmed by fluorescence-activated cell sorting (FACS) analysis and immunoprecipitation. Unless otherwise stated, each clone studied expressed PECAM-1 on its surface on greater than 90% of the cells. At least two independent clones expressing each mutation were studied.
FACS Analysis-L-cells expressing PECAM-1 mutants were removed from T25 flasks (with trypsin for huPECAM-1 constructs and nonenzymatically for muPECAM-1 constructs), washed in medium containing 10% fetal bovine serum, and treated with various anti-PE-CAM-1 monoclonal antibodies for 1 h at 4°C. The primary antibody was then removed, the cells were washed twice with ice-cold phosphatebuffered saline, and a 1:200 dilution of fluorescein isothiocyanate-labeled goat anti-rat or anti-mouse secondary antibody (Cappell) was added for 30 min at 4°C. After washing in cold phosphate-buffered saline, flow cytometry was performed using an Ortho Cytofluorograph 50H cell sorter equipped with a 2150 data handling system (Ortho Instruments, Westwood MA).
Aggregation of L-cell Transfectants-The aggregation assay used in these studies has been described in detail previously (19) . Briefly, stable L-cell transfectants, which had been plated (8 -10 ϫ 10 6 cells/75-cm 2 flask) and grown overnight, were removed with trypsin (for huPE-CAM-1 constructs) or nonenzymatically (for muPECAM-1 constructs). The cells were washed twice with 10 mM EDTA in phosphate-buffered saline, pH 7.2, and twice with HBSS without divalent cations. Cells were finally resuspended to a concentration of approximately 0.8 -1.0 ϫ 10 6 /ml in HBSS with or without 1 mM calcium. After the cells had been dispersed to a single cell suspension, 1-ml aliquots were transferred to wells in a 24-well nontissue culture plastic tray (Costar Corp., Cambridge, MA) that had been previously incubated with 2% bovine serum albumin in HBSS for at least 1 h and washed thoroughly with HBSS immediately before use to prevent nonspecific binding to the plastic of the tray. The trays containing the suspended L-cells were rotated on a gyratory platform (100 rpm) at 37°C for 30 min. Aggregation was quantified by examining representative aliquots from each sample on a hemocytometer grid using phase contrast optics. The number of single cells (cells in aggregates Յ 3) remaining versus those present in aggregates of greater than three cells were counted from four 1-mm squares. At least 400 cells were counted from each sample. Data were expressed as the percentage of total cells present in aggregates.
Mixed Aggregation Assay-These studies were used to determine mechanisms for PECAM-1-dependent L-cell aggregation (homophilic or heterophilic) and identify binding interactions between different L-cell transfectants (19) . In these experiments, L-cell aggregation was performed by mixing two different cell lines, with one of the two cell types fluorescently labeled prior to mixing. After the cell line designated for labeling had been washed once with EDTA, it was resuspended in HBSS to a total volume of 1 ml. One ml of rhodamine-conjugated dye solution at a final concentration of 1 mM (Sigma), in buffer provided by the manufacturer, was added, followed by incubation at room temperature for 5-10 min. Labeling was terminated by adding an equal volume of fetal bovine serum and by washing the cells with HBSS. The second EDTA wash and the two HBSS washes were then performed as described above. Each set of cells, one labeled, and the other unlabeled, were resuspended at 0.8 -1.0 ϫ 10 6 cells/ml. Aliquots of 0.5 ml of each were combined in the wells of a 24-well non-tissue culture-treated plate and allowed to aggregate as described above. After the aggregation was completed, the cells were viewed under epifluorescence. The number of fluorescent cells in each aggregate of a given size was counted. Quantitative analysis of the aggregating cell populations was performed as described by Sieber and Roseman (28) .
RESULTS
Deletion of Exon 14 of huPECAM-1 Results in Homophilic
Aggregation-Previous studies have shown that L-cell fibroblaststransfectedwithfull-lengthhuPECAM-1mediatecalcium-dependent, heterophilic aggregation, while L-cell transfectants expressing a mutant in which exons 14 -16 (huPECAM-1⌬14 -16) were deleted demonstrate aggregation that is homophilic and calcium-independent (23). This suggests that sequences in exons 14, 15, and/or 16 determine the ligand interaction of huPECAM-1.
To further localize these sequences, a mutant was constructed in which exons 15 and 16 (huPECAM-1⌬15, 16) were deleted from the cytoplasmic domain. L-cells transfected with huPECAM-1⌬15,16 behaved like full-length huPECAM-1 and mediated calcium-dependent aggregation (Fig. 3A) that was heterophilic in nature (Fig. 3B) , quite unlike L-cells expressing huPECAM-1⌬14 -16 that bound in a homophilic manner (Fig. 3C) .
These data, along with studies of muPECAM-1 where embryo-derived alternatively spliced cytoplasmic domain variants missing exon 14 mediated calcium-independent homophilic aggregation (25) , suggested that the removal of exon 14 would alter the binding characteristics of huPECAM-1. To test this hypothesis, an additional huPECAM-1 mutant was made in which only exon 14 (huPECAM-1⌬14) was deleted. In contrast to full-length huPECAM-1 and the huPECAM-1⌬15,16 mutants, aggregation of L-cell transfectants expressing huPE-CAM-1⌬14 was found to be calcium-independent and homophilic (Fig. 3D) . At least two independent clones were tested for each construct, and all the transfectants used in these studies expressed PECAM-1 at comparable levels by FACS analysis (mean (log) fluorescence intensities, 100 -120). These findings provide direct evidence that removal of the 18 amino acids in exon 14 can convert the ligand binding of huPECAM-1 from heterophilic to homophilic. 
Deletion of Exons 10 -16 Results in a Loss of PECAM-1-dependent Aggregation-Previous
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a calcium-independent homophilic manner (mixed aggregation data not shown). In contrast, L-cell-expressing huPECAM-1⌬10 -16 were not able to support any form of aggregation (Fig.  4) . At least two independent clones were tested for each construct, and all the transfectants used in these studies expressed PECAM-1 at comparable levels by FACS analysis (mean (log) fluorescence intensities, 100 -120). These data indicate that the minimal length of huPECAM-1's cytoplasmic domain that is required for aggregation resides somewhere within the 10 amino acids of exon 10 plus the five amino acids of exon 9 that are part of the cytoplasmic domain.
Exon 14 May Be Sufficient for Heterophilic AggregationThe data presented above indicate that the loss of exon 14 converts aggregation from a heterophilic to a homophilic process. To determine if the addition of exon 14 to the minimal cytoplasmic domain structure that supported homophilic aggregation was sufficient to induce heterophilic aggregation, a mutant huPECAM-1 was constructed in which exon 14 was added to the homophilic construct huPECAM-1⌬11-16 and designated huPECAM-1(ϩ)9,10,14 ( Fig. 1) . When clones (total number, 3) expressing this construct were analyzed (mean (log) fluorescence intensities, 100 -120), they aggregated in a calciumdependent heterophilic manner (Fig. 5, A and B) , unlike huPECAM-1⌬11-16, which aggregated in a calcium-independent homophilic manner at the same level of surface level expression (Fig. 5, D and E) . These data suggested that the presence of exon 14 could confer heterophilic binding. This conversion to heterophilic binding was not due to a simple increase in the length of the cytoplasmic domain, since L-cells expressing huPECAM-1⌬12-16, a construct of a length compa- FIG. 5 . Aggregation of huPECAM-1(؉)9,10,14 L-cell transfectants. Standard and mixed aggregation studies were performed with L-cell transfectants of huPECAM-1(ϩ)9,10,14 and huPECAM-1⌬11-16. For each construct, clones expressing lower (mean (log) fluorescence intensities, 100 -120) and higher (mean (log) fluorescence intensities, 130 -150) levels of PECAM-1 were tested. The mean (log) fluorescence intensity (MFI) is indicated for each representative clone. In standard aggregation studies (with and without 1 mM calcium) (A and D), huPECAM-1(ϩ)9,10,14 transfectants with lower levels of expression demonstrated calcium-dependent aggregation, while the higher level-expressing transfectants mediated calcium-independent aggregation (A). Low and high expressing clones of huPECAM-1⌬11-16 demonstrated calcium-independent aggregation. The data presented are representative of at least three experiments done in duplicate or triplicate. Standard deviations are shown. In mixed aggregation assays (with 1 mM calcium) (B, C, E, and F) the lower expressing transfectants of huPECAM-1(ϩ)9,10,14 formed mixed aggregates (heterophilic interaction) (B), while the higher expressing clones of huPECAM-1(ϩ)9,10,14 (C) and all the clones of huPECAM-1⌬11-16 (D, E) formed primarily self-aggregates (homophilic interaction). The data are representative of at least three experiments. rable with huPECAM-1(ϩ)9,10,14, aggregated in a homophilic manner.
Surface Expression Levels of PECAM-1(ϩ)9,10,14 Affect the Type of Aggregation-When the huPECAM-1(ϩ)9,10,14 cDNA was transfected into L-cells, six clones were tested for their ability to aggregate. Although three of these clones aggregated in the calcium-dependent heterophilic fashion described above, three clones behaved quite differently and aggregated in a calcium-independent, homophilic manner (Fig. 5, A and C) . Further analysis of these cell lines revealed that these three clones had levels of PECAM-1 expression (mean (log) fluorescence intensities, 131, 140, 155) that were much higher than the clones of the huPECAM-1(ϩ)9,10,14 that aggregated in a heterophilic fashion (mean (log) fluorescence intensities, 100, 111, 118) (Fig. 5B) . This relationship to level of surface expression was not seen with huPECAM-1⌬11-16 (Fig. 5, D, E, and  F) . These data suggested that in addition to the cytoplasmic domain structure of PECAM-1, the surface level of the molecule might also affect the type of aggregation observed.
Overexpression of Full-length PECAM-1 Results in Homophilic Aggregation-To directly test the hypothesis that the level of huPECAM-1 also determines the mechanism of ligand binding, L-cell transfectants expressing higher levels of fulllength PECAM-1 were prepared by cell sorting (see "Experimental Procedures"). Using this approach, three clones were obtained that expressed full-length huPECAM-1 at very high levels (mean (log) fluorescence intensities, 130, 147, 148). For comparison, the expression level of PECAM-1 on cultured hu- man umbilical vein endothelial cells averages approximately 120. In contrast to L-cells expressing full-length huPECAM-1 at levels comparable with endothelial cells clones (3 clones, mean (log) fluorescence intensities 108, 110, 115), these high expressing, full-length huPECAM-1 transfectants were found to mediate aggregation that was calcium-independent and homophilic (Fig. 6, A, B, and C) . Importantly, this biphasic pattern was not seen with huPECAM-1⌬14, where L-cells expressing PECAM-1 at mean fluorescence intensities of Ͻ130 and Ͼ130 behaved similarly (Fig. 6, D, E, and F) . Selection for these higher expressing clones did not change the mobility of PE-CAM-1 on SDS-polyacrylamide gel electrophoresis (data not shown).
The results of the experiments described above with the cytoplasmic domain mutants of huPECAM-1 are summarized in Table I . Taken together these findings indicate that the ligand interactions of huPECAM-1 are influenced both by the presence of exon 14 and the level of surface expression.
Ig-like Domains 1 and 2 Are Required for Homophilic Aggregation-The development of PECAM-1 constructs capable of mediating homophilic adhesion provided the opportunity to identify those regions in the extracellular domain that were required for homophilic PECAM-1-dependent adhesion. Observations from other Ig superfamily members have confirmed that different Ig-like domains mediate different ligand interactions, and thus it was anticipated that the extracellular regions of PECAM-1 that mediate heterophilic interactions might be different from those that are responsible for homophilic adhesion.
When L-cell transfectants of huPECAM-1⌬14 (calcium-independent homophilic binding) were mixed with L-cells expressing full-length huPECAM-1 (calcium-dependent heterophilic binding), in the absence of calcium to prevent heterophilic binding, "mixed aggregates" were detected (Fig. 7A) . Since no calcium was present, the (calcium-dependent) full-length PE-CAM-1 transfectants were unable to initiate the formation of aggregates. Thus, the aggregates that formed were dependent on the homophilic domains in huPECAM-1⌬14 interacting with the appropriate counter-binding region present in the wild-type huPECAM-1.
In contrast, when L-cell transfectants of huPECAM-1⌬14 were mixed in the absence of calcium with an equal number of L-cells expressing full-length muPECAM-1 (calcium-dependent heterophilic binding) or muPECAM-1⌬14 (calcium-independent homophilic binding), there was no evidence of interaction between the two types of cells. This is illustrated in Fig. 7B for full-length muPECAM-1 transfectant (data not shown for muPECAM-1⌬14). These experiments demonstrate that homophilic binding does not occur between human and mouse PECAM-1 and show that the homophilic binding site(s) for huPECAM-1 is not present or unrecognizable in muPECAM-1.
The finding that huPECAM-1⌬14 interacted with wild-type huPECAM-1 but not with muPECAM-1 allowed us to localize the Ig-like domains required for homophilic binding. This was accomplished by constructing huPECAM-1 mutants in which the human Ig-like domains were replaced by the corresponding mouse sequences. The use of human/mouse chimeric receptors allowed us to make rather large changes without significantly disrupting the structural features of the molecule. The two chimeric proteins initially studied were huPECAM-1 mutants in which murine sequences were inserted in place of domains 3-6 (huPECAM-1D3-6 mu ) or domains 1 and 2 (huPECAM-1D1,2 mu ).
When mixed aggregation experiments were performed (without calcium) with L-cell transfectants expressing huPECAM-1⌬14 and each of these additional mutants, it was found that huPECAM-1⌬14 transfectants formed mixed aggregates with huPECAM-1D3-6 mu transfectants (Fig. 7C) but not with Lcell-expressing huPECAM-1D1,2 mu (Fig. 7D) . In contrast, muPECAM-1⌬14 transfectants interacted with huPECAM-1D1,2 mu expressing cells but not with huPECAM-1D3-6 mu transfectants (data not shown). Since huPECAM-1⌬14 does not interact with muPECAM-1, the interaction between huPE-CAM-1⌬14 and huPECAM-1D3-6 mu must involve the human sequences of domains 1 and 2.
To determine if domain 1, domain 2, or both were required for homophilic aggregation, two additional chimeric constructs were made in which either domain 1 (huPECAM-1D1 mu ) or domain 2 (huPECAM-1D2 mu ) of huPECAM-1 was replaced by the corresponding murine domain. In the absence of calcium, L-cells expressing huPECAM-1⌬14 did not form mixed aggregates with transfectants expressing huPECAM-1D1 mu or hu-PECAM-1D2 mu . (Fig. 7, E and F) . Similarly, L-cells expressing muPECAM-1⌬14 did not interact with either huPECAM-1D1 mu or huPECAM-1D2 mu transfectants (data not shown). These data are summarized in Table II and suggest that both domains 1 and 2 participate together in mediating PECAM-1-dependent homophilic adhesion.
DISCUSSION
In order to better understand the mechanism of PECAM-1-dependent homophilic adhesion, the behavior of murine L-cell fibroblasts expressing full-length and selectively mutated forms of huPECAM-1 were analyzed in a well-defined cell-cell aggregation assay. The results of these experiments indicate that 1) the minimal length of the cytoplasmic domain required for cellular aggregation is represented within exons 9 and 10; 2) removal of exon 14 from the cytoplasmic domain changes the mechanism of aggregation from a heterophilic calcium-dependent process to a homophilic calcium-independent interaction; 3) the presence of exon 14 may be sufficient for calcium-dependent heterophilic aggregation; 4) high levels of surface expression of PECAM-1 on the cell surface change the mechanism of aggregation from heterophilic to homophilic; and 5) PECAM-1-dependent homophilic binding appears to involve direct interaction of only the first two extracellular Ig-like domains (Tables  I and II) .
Structure/Function Relationships-The experiments described above were designed to provide information about the specific regions of PECAM-1 involved in regulating its adhesive function. The finding that deletion of exon 14 from huPECAM-1 led to a calcium-independent homophilic interaction is consistent with the studies of muPECAM-1, where embryo-derived alternatively spliced cytoplasmic domain variants missing exon 14 also mediated calcium-independent homophilic aggregation (25) . More precise localization of this key region is currently ongoing, but preliminary data suggest that the 3Ј half of 
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exon 14 (sequence, YSEIRKVDP) contains the important sequences. 2 The mechanism by which removal of exon 14 from the wild-type huPECAM-1 alters the ligand binding is currently uncertain. The simplest explanation is that deletion of exon 14 directly results in a conformational change that favors homophilic adhesion over heterophilic adhesion. Since the terminal residue of exon 14 is a proline, loss of this amino acid may interfere with the ability of the cytoplasmic domain to fold properly. However, the finding that the addition of exon 14 may be sufficient to restore calcium-dependent heterophilic aggregation suggests that more than a simple change in the conformation may be involved. PECAM-1 possesses a long cytoplasmic domain (118 amino acids) with numerous residues available for post-translational modifications and/or proteinprotein interactions that might provide functional regulation. To determine the extracellular Ig-like domains required for homophilic aggregation, studies were done in which L-cell transfectants of huPECAM-1⌬14 were mixed (without calcium) with L-cells expressing huPECAM-1, muPECAM-1, and several huPECAM-1/muPECAM-1 chimeric mutants. Under these conditions all adhesion is initiated by the homophilic domain huPECAM-1⌬14. L-cell transfectants of huPECAM-1⌬14 interacted with cells expressing huPECAM-1 (A) but not muPECAM-1 (B) to form mixed aggregates. In similar experiments, huPECAM-1⌬14 transfectants formed mixed aggregates with transfectants of huPECAM-1D3-6 mu (first two domains human) (C) but not with transfectants of huPECAM-1D1,2 mu (first two domains murine) (D), huPECAM-1D1 mu (domain 1 murine) (E), or huPECAM-1D2 mu (domain 2 murine). These data suggest that both domains 1 and 2 are required for homophilic adhesion. The data are representative of at least two experiments. Given the presence of five potentially phosphorable amino acids in exon 14 (including a tyrosine in the context of a possible SH2 binding domain-YSEI), an alternative mechanism may be that a critical phosphorylation site is lost with the deletion of exon 14. Experiments are currently under way to resolve this question.
A second series of mutants was designed to determine the minimal length of huPECAM-1's cytoplasmic domain that was required for aggregation. These studies revealed that this key region is quite close to the transmembrane region, specifically residing somewhere within the 10 amino acids of exon 10 and/or the five amino acids of exon 9 that are part of the cytoplasmic domain. Although it is currently unclear which, if any, of these amino acids are specifically required, a number of interesting possibilities are being examined. In this region there are several residues that might provide sites for phosphorylation (a tyrosine at position 596 and a serine at position 611) or addition of lipids (a cysteine at residue 595 fits the criteria for palmitylation) that could be important in regulating the adhesive function of PECAM-1.
Regulation of PECAM-1 Ligand Binding by Surface Density-One of the most interesting findings in this study was the observation that the level of surface expression of PECAM-1 determined the type of ligand interaction (Fig. 6 ). To our knowledge this has not been previously described for a member of the immunoglobulin superfamily and helps to resolve a previously unexplained difference reported in the literature regarding the function of muPECAM-1. Xie and Muller (29) reported that wild-type muPECAM-1 mediated calciumindependent homophilic L-cell aggregation. In contrast, our group observed that full-length muPECAM-1 mediated calciumdependent heterophilic aggregation (25) . Subsequent FACS analysis of the muPECAM-1 L-cell transfectant clone of Xie and Muller used in their paper (kindly provided by Dr. William Muller, Rockefeller University) reveals that this clone expresses muPECAM-1 at exceptionally high levels (mean (log) fluorescence intensity Ͼ150) compared with those used by us (mean (log) fluorescence intensities Ͻ120).
3 These data are consistent with the findings of this paper with huPECAM-1 and support the conclusion that the amount of surface PE-CAM-1 is important in regulating the mechanism of ligand binding. The finding that the local level of surface expression of PE-CAM-1 alters its ligand binding properties may have important in vivo implications. For example, these data suggest that for endothelial cells, where PECAM-1 expression is high (30), particularly at endothelial cell-cell junctions (31, 32) , that the ligand interaction for PECAM-1 is very likely to be homophilic. On the other hand, on leukocytes, where the expression of PECAM-1 is lower and more diffuse (30) , PECAM-1 may meditate primarily heterophilic binding. This hypothesis is supported by the observation that PECAM-1 on U937 cells and on hematopoietic precursor cells is able to bind to heparinSepharose (18) .
The Extracellular Domains of PECAM-1 Important for Homophilic Interactions-Fawcett and associates (16) have examined the ability of COS cells transfected with huPECAM-1 to bind to chimeric proteins of huPECAM-1 fused with human Fc immobilized on plastic. They have proposed that PECAM-1-dependent homophilic adhesion involves an interaction in which PECAM-1 molecules on adjacent cells overlap each other in an antiparallel manner with engagement of specific binding sites in Ig-like domains 2 and 3 and domains 5 and 6. In contrast, the recent results of Sun et al. (26) , who also examined huPE-CAM-1 binding with a recombinant PECAM-1/IgG chimeric protein, suggest that only Ig-like domains 1 and 2 are involved. Our findings, which examine PECAM-1 in a fully cellular system, also indicate that PECAM-1-mediated homophilic binding is specifically regulated only by interactions involving the first two Ig-like domains, although it is likely that the other four extracellular Ig-like domains play an important accessory role in maintaining domains 1 and 2 in the proper spatial context (see below). Therefore, for PECAM-1-mediated homophilic adhesion, we propose an antiparallel interaction in which domain 1 of one PECAM-1 molecule binds to domain 2 of the counter molecule of PECAM-1 (Fig. 8) .
Differences in the assays used and the nature of the constructs may potentially account for these discrepant results. The assay used by Fawcett et al. involved the binding of COS cells expressing full-length huPECAM-1 to chimeric proteins of huPECAM-1 fused with human Fc immobilized on plastic. Our system, by contrast, was one in which PECAM-1-PECAM-1 interactions occurred in a totally cellular context. This distinction is likely to be important. For example, recent studies of integrins indicate that experiments using immobilized purified integrins and in vitro biochemical techniques may not accurately reflect the true interactions of these receptors when expressed on the cell surface (33) . Differences in the type of mutants employed may also be significant. Fawcett and associates used soluble recombinant forms of PECAM-1 that were 3 H. M. DeLisser, unpublished observations. without cytoplasmic domains and of different lengths. The importance of the cytoplasmic domain has been documented in this study and our previous work (23, 25) . In addition, no controls were examined to account for the importance of the length of the constructs used in the Fawcett et al. (16) study. The significance of extracellular domain length has been recently demonstrated for P-selectin, where optimal binding of P-selectin to its ligand PSGL-1 requires that its ligand binding domain project a significant distance above the cell membrane surface (34) . In support of this concept, we have noted that L-cells expressing truncation mutants containing only the first two Ig-like domains of huPECAM-1 connected to the PECAM-1 transmembrane and cytoplasmic domains bind minimally to homophilic binding forms of huPECAM-1. 3 This contrasts with the behavior of the human/mouse chimeric molecule expressing only the first two human Ig-like domains that was able to interact with homophilic mutants of huPECAM-1 (Fig. 7C) . We propose that the distance of the ligand binding region (i.e. domains 1 and 2) above the cell surface is also important for PECAM-1. All of our extracellular domain mutants carried an intact cytoplasmic tail, and since chimeric human-mouse PE-CAM-1 mutants were used, we were able to preserve the normal length and tertiary structure of the molecule.
A better understanding of the precise regions of interactions of PECAM-1 may be significant from a practical perspective. PECAM-1 appears to be involved in the migration of neutrophils across the endothelium during an acute inflammatory response (7) (8) (9) (10) . Recently, a polyclonal antibody against PE-CAM-1 has been shown to block ischemia/reperfusion injury, suggesting that inhibition of PECAM-1 function may have therapeutic implications (9) . Given the data in this report, and as well as of others (16, 20, 26) , that PECAM-1-dependent adhesion (homophilic or heterophilic) is mediated by domain 1 and/or 2, it is very likely that effective anti-PECAM-1 agents will be directed against the first two Ig-like domains.
Model of PECAM-1-mediated Interactions (Fig. 8) -The regulation of PECAM-1 function by surface density suggests that clustering of the molecule may play a key role in its function. The recent demonstration that the formation of dimers may be important in the function of ICAM-1, another cell adhesion molecule of the Ig-superfamily (35) , supports this hypothesis. We therefore offer the following conceptual model of PECAM-1-dependent adhesion (Fig. 8) . We hypothesize that on the cell surface, PECAM-1 exits in equilibrium as either a single chain protein or a dimeric molecule. The single chain molecule has a conformation that favors heterophilic adhesion through interactions with domain 2, while the conformation of the PECAM-1 as a dimer allows for homophilic binding mediated by the first two Ig-like domains. The equilibrium between the two forms, and hence the dominant ligand interaction, is determined by the level of surface PECAM-1 and/or the functional state of the cytoplasmic domain. Ligand binding could thus be potentially regulated by alternative splicing (by inclusion or exclusion of exon 14), changes in phosphorylation state (36, 37) , cytoskeletal interactions (36, 38) , or associations with other cytoplasmic proteins. We have recently observed for human umbilical vein endothelial cells that TNF-␣ and interferon-␥ induced a redistribution of PECAM-1 away from cell-cell borders that was associated with decreased PECAM-1-cytoskeletal interactions (38) . Given this model, it is tempting to speculate that cytoskeletal interactions concentrate PECAM-1 at cell borders, resulting in enhanced dimer formation and subsequent homophilic adhesion. Cytokines might disturb this process by altering PECAM-1's interactions with the cytoskelton and/or by interfering with dimerization. Studies are under way to define the role that dimerization might play in the ligand binding of PECAM-1. Ultimately, binding of PECAM-1 to its ligand (whether homophilic or heterophilic) accomplishes cellcell adhesion and/or triggers signaling phenomena.
